Ra. Mcdonald et al., EVOLUTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENV SEQUENCE VARIATION IN PATIENTS WITH DIVERSE RATES OF DISEASE PROGRESSION AND T-CELL FUNCTION, Journal of virology, 71(3), 1997, pp. 1871-1879
We examined the relationship between env sequence variation and diseas
e progression in 10 human immunodeficiency virus type 1 (HIV-1)-seropo
sitive subjects selected from a longitudinal cohort receiving zidovudi
ne therapy. Five subjects were chosen for stable clinical status and C
D4 counts (slow progressors), and five were selected for rapid clinica
l deterioration and CD4 count decline (rapid progressors). The slow pr
ogressors had significantly lower plasma viral RNA loads and greater l
ymphoproliferative responses to mitogens than the rapid progressors. D
NA sequences representing the C1 through C3 regions of env were amplif
ied from two peripheral blood mononuclear cell DNA samples from each s
ubject separated by an average of 2.5 years. Molecular clones of these
amplicons were then sequenced, and DNA sequence and deduced amino aci
d sequence distances were compared. Inter-time point sequence comparis
on showed a higher rate of sequence evolution for the rapid progressor
s in three of five matched pairs of rapid progressors and slow progres
sors and for the slow progressors in the remaining two subject pairs.
However, intra-time point sequence comparisons showed that four of fiv
e slow progressors developed a more diverse quasispecies over time and
one showed no change. In contrast, four of five rapid progressors sho
wed no change in quasispecies diversity over time and one showed a sig
nificant decrease in diversity. The overall C1 through C3 region quasi
species diversity in the slow progressors at baseline was lower than t
hat for the rapid progressors, but this difference was not significant
at the follow-up time points. These diversity relationships were obsc
ured if sequence analyses were limited to the 300-bp C2 to V3 region.
Thus, HIV-1 quasispecies diversity increased over time in subjects wit
h more functional immune systems.